Tech Company Financing Transactions
Gradalis Funding Round
Gradalis, based in Carrollton, received $24 million in investment from private investors.
Transaction Overview
Company Name
Announced On
1/4/2013
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Series B
Investors
Proceeds Purpose
Gradalis will use the funding to advance its autologous vaccine platform, FANG, through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch of FANG. In addition, the funding will be used to progress the clinical and preclinical development of the company's bifunctional shRNA platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2545 Golden Bear Dr. 110
Carrollton, TX 75006
USA
Carrollton, TX 75006
USA
Phone
Website
Email Address
Overview
My Website Pronto is more than a web site company -- we actively participate in a community of small businesses that support one another and share information. By being involved, we are able to clearly understand our clients' needs and ensure that we provide them with the best customer service.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Shanahan
Chief Medical Officer
Luisa anning
Chief Operating Officer
Ernest Bognar
Chief Scientific Officer
John Nemunaitis
VP - Regulatory Affairs
Gladice Wallraven
Browse more venture capital transactions:
Prev: 1/4/2013: Pluralsight venture capital transaction
Next: 1/4/2013: EndoChoice venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs